← Back to GLP-1 DatabaseActive Ingredient tirzepatide Drug Class Dual GIP/GLP-1 Receptor Agonist Dosage & Administration Injectable Approved Indications Weight Loss FDA Approved November 8, 2023
Zepbound
tirzepatide
Dual GIP/GLP-1 Receptor AgonistInjectableWeight Loss
Manufacturer: Eli LillyFDA Approved: November 8, 2023Starting from $1100.00/mo
Overview
Zepbound is a tirzepatide injection specifically approved for chronic weight management, offering the same dual-action mechanism as Mounjaro.
Clinical Data
Weight Loss Efficacy
~21-26% body weight loss in clinical trials
Common Side Effects
nauseadiarrheavomitingconstipationinjection site reactions
Community Side-Effect Reports
User-reported data — not medical advice. Consult your healthcare provider.
Provider Pricing
Ro
$1299.00/mo
✓Consultation included
Hims & Hers
$1399.00/mo
✓Consultation included
Mochi Health
$1100.00/mo
+ consultation fee: $50.00
PlushCare
$1400.00/mo
+ consultation fee: $129.00
Calibrate
$1300.00/mo
✓Consultation included